Trial Changes First-Line Approach for Most Common Breast Cancer Subtype

(MedPage Today) — CHICAGO — Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the benefit of first-line therapy in hormone receptor (HR)-positive…